CoChat

Management of Osteoarthritis: Expert Opinion on NSAIDs

Open access

The DOI matches its Crossref record; 103 of the 106 references it cites were found in a registry or an index.

Abstract

Osteoarthritis (OA) is a leading cause of disability among older adults worldwide. Treatment aims are to alleviate inflammatory pain and improve physical function through non-pharmacological and pharmacological interventions. Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended as first-line therapy. However, selection is challenged by patient age, comorbidities and polypharmacy, and by the drug's benefit/risk balance, all of which together influence the risk of cardiovascular (CV), gastrointestinal (GI) and renal adverse events (AEs). While the efficacy profile of the various NSAIDs is delineated, the differences in their safety profile are not straightforward. This narrative review provides practical indications by a multidisciplinary Italian expert panel for general practitioners and specialists managing OA patients with chronic inflammatory pain; the goal is to maximize therapy efficacy while reducing untoward effects caused by inappropriate NSAID use. The discussion on the best approach to NSAIDs spanned the following topics: (1) patient evaluation: investigate pain origin, duration and components together with possible risk factors for CV, GI and renal AEs; (2) non-pharmacological interventions: the physiatrist provides a person-centered, holistic approach accounting for all patient aspects; (3) pharmacological interventions: patient profile and drugs' pharmacological properties affect NSAID selection, which drugs to be used in combination or to be avoided, formulation and therapy duration; (4) the pharmacologist's, general practitioner's and pain therapist's points of view; (5) NSAID safety: the individual baseline risk and the drug's safety profile are major determinants of CV, GI and renal risk; consider possible drug-drug interactions; (6) periodical re-evaluation of treatment response and adherence, using scales to assess pain and function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40122-021-00260-1

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The ideal pathway for osteoarthritis patients suffering from chronic inflammatory pain. GP General practitioner, NSAIDs non-steroidal anti-inflammatory drugs
Fig. 1 The ideal pathway for osteoarthritis patients suffering from chronic inflammatory pain. GP General practitioner, NSAIDs non-steroidal anti-inflammatory drugsCC BY-NC · PubMed Central
Fig. 2 The main adverse events observed in osteoarthritis patients upon NSAID therapy (see text for discussion). AKI Acute kidney injury, AMI acute myocardial infarction, CKD chronic kidney disease, COX cyclooxygenase, coxibs COX-2 inhibitors, CV cardiovascular, GFR glomerular filtration rate, GI gastrointestinal, tNSAIDs traditional non-steroidal anti-inflammatory drugs, TXA2 thromboxane A2
Fig. 2 The main adverse events observed in osteoarthritis patients upon NSAID therapy (see text for discussion). AKI Acute kidney injury, AMI acute myocardial infarction, CKD chronic kidney disease, COX cyclooxygenase, coxibs COX-2 inhibitors, CV cardiovascular, GFR glomerular filtration rate, GI gastrointestinal, tNSAIDs traditional non-steroidal anti-inflammatory drugs, TXA2 thromboxane A2CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 103 references

Research works printed but not linked: 3

  1. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman’s: The pharmacological basis of therapeutics, 13th edition. New York: McGraw-Hill Education; 2018.
  2. Burton ME. Applied pharmacokinetics & pharmacodynamics: principles of therapeutic drug monitoring. Philadelphia: Lippincott Williams & Wilkins; 2006.
  3. Institute of Medicine (US) Committee on Quality of Health Care in America. Crossing the quality chasm: a new health system for the 21st century. Washington DC: National Academies Press; 2001. http://www.ncbi.nlm.nih.gov/books/NBK222274/. Accessed 25 Jun 2019.

Cited by

See all 227

Metadata

Authors
Magni, A., Agostoni, P., Bonezzi, C., Massazza, G., Menè, P., Savarino, V., & Fornasari, D.
Affiliations
  • University of Milan (IT)
  • Istituti Clinici Scientifici Maugeri (IT)
  • Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
  • University of Genoa (IT)
Corresponding author
Fornasari, Diego
Venue
Pain and Therapy
Published
2021-04-19
Volume
10
Issue
2
Pages
783-808
ISSN
  • 2193-651X (ISSN-L)
  • 2193-8237
OpenAlex
W3156408207
Cited by
201
References
106
Citations by year
2026: 42 · 2025: 64 · 2024: 46 · 2023: 26 · 2022: 14 · 2021: 9
FWCI
3.88
Type
journal article
Language
en
Open access
Licence
Locations
  • Pain and Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, cc-by-nc)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, cc-by-nc)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by-nc)
Funders
Alfasigma SpA
Topics
  • Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
  • Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Musculoskeletal pain and rehabilitation
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Keywords
osteoarthritis, nonsteroidal anti-inflammatory drugs, NSAID selection, NSAID safety, cardiovascular adverse events, gastrointestinal adverse effects, renal adverse effects, drug-drug interactions, polypharmacy, non-pharmacological treatment, rehabilitation medicine, chronic inflammatory pain, medication adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management of Osteoarthritis: Expert Opinion on NSAIDs. https://app.cochat.ai/papers/10.1007/s40122-021-00260-1
The paper
Magni, A., Agostoni, P., Bonezzi, C., Massazza, G., Menè, P., Savarino, V., & Fornasari, D. (2021). Management of Osteoarthritis: Expert Opinion on NSAIDs. Pain and Therapy. https://doi.org/10.1007/s40122-021-00260-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.